F m Investments LLC Has $3.82 Million Stake in KalVista Pharmaceuticals, Inc. $KALV

F m Investments LLC raised its position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) by 18.8% during the 4th quarter, HoldingsChannel.com reports. The firm owned 236,690 shares of the specialty pharmaceutical company’s stock after purchasing an additional 37,486 shares during the period. F m Investments LLC’s holdings in KalVista Pharmaceuticals were worth $3,823,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of KALV. Tudor Investment Corp ET AL acquired a new stake in shares of KalVista Pharmaceuticals in the 3rd quarter valued at about $24,360,000. Parkman Healthcare Partners LLC raised its stake in shares of KalVista Pharmaceuticals by 155.5% in the 3rd quarter. Parkman Healthcare Partners LLC now owns 1,735,003 shares of the specialty pharmaceutical company’s stock valued at $21,132,000 after purchasing an additional 1,055,940 shares during the period. Ameriprise Financial Inc. raised its stake in shares of KalVista Pharmaceuticals by 2,258.6% in the 2nd quarter. Ameriprise Financial Inc. now owns 945,125 shares of the specialty pharmaceutical company’s stock valued at $10,685,000 after purchasing an additional 905,053 shares during the period. Freestone Grove Partners LP bought a new position in shares of KalVista Pharmaceuticals in the 3rd quarter valued at about $8,580,000. Finally, Schroder Investment Management Group grew its holdings in shares of KalVista Pharmaceuticals by 108.7% in the 3rd quarter. Schroder Investment Management Group now owns 1,158,457 shares of the specialty pharmaceutical company’s stock valued at $14,145,000 after acquiring an additional 603,499 shares in the last quarter.

Insider Buying and Selling at KalVista Pharmaceuticals

In other KalVista Pharmaceuticals news, insider Nicole Sweeny sold 3,975 shares of the business’s stock in a transaction that occurred on Monday, February 23rd. The shares were sold at an average price of $15.57, for a total transaction of $61,890.75. Following the completion of the transaction, the insider directly owned 47,003 shares in the company, valued at $731,836.71. The trade was a 7.80% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Brian Piekos sold 1,862 shares of the business’s stock in a transaction that occurred on Friday, April 17th. The shares were sold at an average price of $20.22, for a total transaction of $37,649.64. Following the transaction, the chief financial officer owned 18,150 shares of the company’s stock, valued at approximately $366,993. This represents a 9.30% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders sold 263,969 shares of company stock valued at $4,536,178. 4.30% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the company. Leerink Partners cut KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, April 29th. JonesTrading cut KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, April 30th. Needham & Company LLC cut KalVista Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, April 30th. Stifel Nicolaus boosted their price objective on KalVista Pharmaceuticals from $39.00 to $42.00 and gave the stock a “buy” rating in a report on Thursday, March 26th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a research report on Tuesday, April 21st. Three investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $30.60.

KalVista Pharmaceuticals Stock Up 0.0%

Shares of KALV opened at $26.73 on Friday. KalVista Pharmaceuticals, Inc. has a one year low of $9.83 and a one year high of $26.84. The company has a market cap of $1.37 billion, a P/E ratio of -6.77 and a beta of -0.12. The company has a debt-to-equity ratio of 8.18, a current ratio of 7.22 and a quick ratio of 7.21. The firm has a 50 day simple moving average of $19.11 and a two-hundred day simple moving average of $16.10.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.